What is the first-line treatment for persistent allergic rhinitis?

What is the first-line treatment for persistent allergic rhinitis?

• A. Oral antibiotics
• B. Antihistamines alone without education
• C. Intranasal corticosteroids in addition to allergen avoidance and patient education
• D. Immunotherapy only

Answer: (C)

Managing persistent allergic rhinitis starts with reducing nasal inflammation while ensuring the patient understands how to avoid triggers. Intranasal corticosteroids are the most effective first-line pharmacologic therapy because they directly target the nasal mucosa to relieve all major symptoms—congestion, sneezing, itching, and rhinorrhea—and improve overall quality of life. When used regularly, they provide rapid and sustained relief with a favorable safety profile, especially when dosing is appropriate and technique is correct. Pairing intranasal corticosteroids with allergen avoidance and patient education is essential. Avoidance lowers exposure to triggers, and education—covering correct spray technique, adherence, and realistic expectations—improves effectiveness and consistency of use. This combination addresses both the underlying inflammation and the real-world factors that influence control. Other options don’t fit as first-line. Antibiotics aren’t useful for allergic rhinitis since it’s not an infection. Antihistamines alone may help some sneezing and itching but often don’t adequately control nasal obstruction or long-term inflammation, and they don’t replace the need for trigger management and proper technique. Immunotherapy can be beneficial for certain patients with specific allergen sensitivities, particularly for long-term disease modification, but it isn’t considered a first-line stand-alone treatment compared with intranasal steroids plus avoidance and education.

Managing persistent allergic rhinitis starts with reducing nasal inflammation while ensuring the patient understands how to avoid triggers. Intranasal corticosteroids are the most effective first-line pharmacologic therapy because they directly target the nasal mucosa to relieve all major symptoms—congestion, sneezing, itching, and rhinorrhea—and improve overall quality of life. When used regularly, they provide rapid and sustained relief with a favorable safety profile, especially when dosing is appropriate and technique is correct.

Pairing intranasal corticosteroids with allergen avoidance and patient education is essential. Avoidance lowers exposure to triggers, and education—covering correct spray technique, adherence, and realistic expectations—improves effectiveness and consistency of use. This combination addresses both the underlying inflammation and the real-world factors that influence control.

Other options don’t fit as first-line. Antibiotics aren’t useful for allergic rhinitis since it’s not an infection. Antihistamines alone may help some sneezing and itching but often don’t adequately control nasal obstruction or long-term inflammation, and they don’t replace the need for trigger management and proper technique. Immunotherapy can be beneficial for certain patients with specific allergen sensitivities, particularly for long-term disease modification, but it isn’t considered a first-line stand-alone treatment compared with intranasal steroids plus avoidance and education.